Gastroprotected Superoxide Dismutase in Combination With UVB vs Placebo and UVB for Treating Vitiligo.

• Status: Active, not recruiting
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The role of the oxidative stress in vitiligo is supported by many studies but robust data are lacking concerning their interest as therapeutic agents. The objective of the study is to compare the association of GLISODIN (a gastro-protected superoxide dismutase) and Nb-UVB to Nb-UVB and placebo for treating vitiligo.

Adult patients with non-segmental vitiligo affecting more than 5% of body surface area will be included.

The main criteria of evaluation will be the VES score at 6 months compared to baseline in both groups.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire de Nice
• Treatments: Superoxide Dismutase

Criteria

Inclusion Criteria:

• Vitiligo

• Vitiligo, SOD, UVB

• Non-segmental vitiligo with BSA>5%

Exclusion Criteria:

• Criteria of non-inclusion

• Segmental or mixed vitiligo

• Pregnancy

• Vitiligo lesions localized only on hands and feet

• Immuno-suppressive drugs

• Corticosteroids

• Photosensitive drugs

• Photodermatosis

• Personal history of skin cancer

• Allergy to gluten